The present invention relates to the use of p38 MAP kinase inhibitors and p38 MAP kinase inhibition to promote wound healing.
1. A topical application wound dressing, comprising:
a wound contacting layer; and
a topical formulation comprising a therapeutically effective amount of a p38 MAP kinase inhibitor or a pharmaceutically acceptable salt thereof;
wherein the inhibitor is dispersed in or on the wound contacting layer and has the following structure
and wherein the topical formulation is not suitable for systemic administration.
2. The wound dressing of claim 1 , wherein the topical formulation further comprises at least one carrier selected from the group consisting of a hydrogel comprising a cellulose derivative and a hydrogel comprising a polyacrylic acid.
3. The wound dressing of claim 2 , wherein the at least one carrier is selected from the group consisting of hydroxyethyl cellulose, hydroxymethyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose, and a mixture thereof.
4. The wound dressing of claim 1 , wherein the wound contacting layer comprises a film, a textile material, a foam, or a hydrogel.
5. The wound dressing of claim 1 , wherein the wound contacting layer comprises a slow-release solid matrix.
6. The wound dressing of claim 1 , wherein the wound contacting layer comprises a biodegradable sheet material.
7. The wound dressing of claim 4 , wherein the textile material is a woven or non-woven textile material.
8. The wound dressing of claim 4 , wherein the foam is a polyurethane foam.
9. The wound dressing of claim 4 , wherein the hydrogel is selected from the group consisting of polyurethane hydrogel, a polyacrylate hydrogel, a gelatin hydrogel, a carboxymethyl cellulose hydrogel, a pectin hydrogel, an alginate hydrogel, a hyaluronic hydrogel, and a combination thereof.
10. The wound dressing of claim 5 , wherein the slow-release solid matrix comprises alginate, collagen, or a synthetic bioabsorbable polymer.
11. The wound dressing of claim 6 , wherein the biodegradable sheet material provides sustained release of the p38 MAP kinase inhibitor.
12. The wound dressing of claim 11 , wherein the biodegradable sheet material is a sheet of freeze-dried collagen, a sheet of freeze-dried collagen/alginate mixture, or a sheet of freeze-dried collagen/oxidized regenerated cellulose.